Surgery for Idiopathic Full-Thickness Macular Hole: Two-Year Results of a Randomized Clinical Trial Comparing Natural History, Vitrectomy, and Vitrectomy Plus Autologous Serum: Moorfields Macular Hole Study Group Report No. 1

Archives of Ophthalmology

Volumn 122, Issue 2, 2004, Pages 224-236

  Ezra, Eric ^a   Gregor, Zdenek J ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CATARACT EXTRACTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA HOLE; SERUM; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VISION; VISUAL ACUITY; VITRECTOMY;

AGED; BLOOD; DOUBLE-BLIND METHOD; EPIRETINAL MEMBRANE; FEMALE; FLUOROCARBONS; FOLLOW-UP STUDIES; HUMANS; MALE; RETINAL PERFORATIONS; SAFETY; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

EID: 0842327150     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.2.224     Document Type: Article

References (82)

1. Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes: results of a pilot study. Arch Ophthalmol. 1991;109:654-659.
2. Wendel RT, Patel AC, Kelly NE, Salzano TC, Wells JW, Novack GD. Vitreous surgery for macular holes. Ophthalmology. 1993;100:1671-1676.
3. Glaser BM, Michels RG, Kupperman BD, et al. The effects of pars plana vitrectomy and transforming growth factor-beta 2 for the treatment of full-thickness macular holes: a prospective randomized study. Ophthalmology. 1992;99:1162-1173.
4. Lansing MB, Glaser BM, Liss H, et al. The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes. Ophthalmology. 1993;100:868-871.
5. Orrellana J, Lieberman RM. Stage III macular hole surgery. Br J Ophthalmol. 1993;77:555-558.
6. Smiddy WE, Glaser BM, Thompson JT, et al. Transforming growth factor-beta 2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes: preliminary anatomic results of a multicentre prospective randomized study. Retina. 1993;13:296-301.
7. Ryan EH, Gilbert HD. Results of surgical treatment of recent-onset full-thickness idiopathic macular holes. Arch Ophthalmol. 1994;112:1545-1553.
8. Ruby AJ, Williams DF, Grand MG, et al. Pars plana vitrectomy for treatment of stage 2 macular holes. Arch Ophthalmol. 1994;112:359-364.
9. Wells JA, Gregor ZJ. Surgical treatment of full-thickness macular holes using autologous serum. Eye. 1996;10:593-599.
10. Kim JW, Freeman WR, Azen SP, et al. Prospective randomized trial of vitrectomy for stage 2 macular holes. Am J Ophthalmol. 1996;121:605-614.
11. Freeman WR, Azen SP, Kim JW, et al. Vitrectomy for the treatment of full-thickness stage 3 or 4 macular holes: results of a multicenter randomized controlled trial. Arch Ophthalmol. 1997;115:11-22.
12. Ezra E, Aylward WG, Gregor ZJ. Membranectomy and autologous serum for the retreatment of full-thickness macular holes. Arch Ophthalmol. 1997;115:1276-1280.
13. Kim JW, Freeman WR, El-Haig W, Maguire AM, Arevalo JF, Azen SP. Baseline characteristics, natural history, and risk factors to progression in eyes with stage 2 macular holes: results from a prospective randomized clinical trial. Ophthalmology. 1995;102:1818-1829.
14. Thompson JT, Smiddy WE, Williams GA, et al. Comparison of recombinant trans forming growth factor beta-2 and placebo as an adjunctive agent for macula hole surgery. Ophthalmology. 1998;105:700-706.
15. Thompson JT, Sjaarda RN, Glaser BM, Murphy RP. Increased intraocular pressure after macular hole surgery. Am J Ophthalmol. 1996;121:615-622.
16. Liggett PE, Skolik S, Horio B, et al. Human autologous serum for the treatmen of full thickness macular holes: a preliminary study. Ophthalmology. 1995;102 1071-1076.
17. Christmas NJ, Skolik SA, Howard MA, Saito Y, Barnstable CJ, Liggett PE. Treatment of retinal breaks with autologous serum in an experimental model. Ophthalmology. 1995;102:263-271.
18. Gaudric A, Massin P, Paques M, et al. Autologous platelet concentrate for the treatment of full thickness macular holes. Graefes Arch Clin Exp Ophthalmol. 1995:233:549-554.
19. Paques M, Chastang C, Mathis A, et al. Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicentre, double-masked, randomised trial. Ophthalmology. 1999;106:932-938.
20. Korobelnik JF, Hannouche D, Belayachi N, et al. Autologous platelet concentrate as an adjunct in macular hole surgery: a pilot study. Ophthalmology. 1996;103:590-594.
21. Blumenkranz MS, O'Hana E, Shaik S, et al. Adjuvant methods in macular hole surgery: intraoperative plasma-thrombin mixture and postoperative fluid-gas exchange. Ophthalmic Surg Lasers. 2001;32:198-207.
22. Iwasaki T, Sanda A, Yamamoto K, Okade A, Usui NM. The use of fibrin tissue adhesive in the treatment of macular holes. Invest Ophthalmol Vis Sci. 1995;36:1050-1056.
23. Tilanus MA, Deutman AF. Full-thickness macular holes treated with vitrectomy and tissue glue. Int Ophthalmol. 1994-95;18:355-358.
24. Olsen TW, Sternberg P, Martin DF, et al. Postoperative hypopyon after intravitreal bovine thrombin for macular hole surgery. Am J Ophthalmol. 1996;121:575-577.
25. Thompson JT, Glaser BM, Sjaarda RN, et al. Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor beta-2. Ophthalmology. 1994;101:1195-1200.
26. Ryan EA, Lee S, Chern S. Use of intravitreal autologous blood to identify the posterior cortical vitreous in macular hole sugery. Arch Ophthalmol. 1995;113:822-823.
27. Lewis JM, Park I, Ohji M, et al. Diamond-dusted silicone cannula for epiretinal membrane separation during vitreous surgery. Am J Ophthalmol. 1997;124:552-554.
28. Margherio RR, Margherio AR, Williams GA, Chow DR, Banach MJ. Effect of perifoveal tissue dissection in the management of acute idiopathic full-thickness macular hole. Arch Ophthalmol. 2000;118:495-498.
29. Cheng L, Freeman WR, Ozerdem U, Song MK, Azen SP. Prevalence, correlates and natural history of epiretinal membrane surrounding idiopathic macular holes: Vitrectomy for Macular Hole Study Group. Ophthalmology. 2000;107:853-859.
30. Olsen TW, Sternberg P, Capone A, et al. Macular hole surgery using thrombin-activated fibrinogen and selective removal of the internal limiting membrane. Retina. 1998;18:322-329.
31. Park DW, Sipperly JO, Sneed SR, Dugel PU, Jacobsen J. Macular hole surgery with internal limiting membrane peeling and intravitreous air. Ophthalmology. 1999;106:1392-1397.
32. Freeman WR, Azen SP. Evaluation of new techniques in macular surgery. Ophthalmology. 1999;106:861-862.
33. Mester V, Kuhn F. Internal limiting membrane removal in the management of full-thickness macular hole. Am J Ophthalmol. 2000;129:769-777.
34. Kadonosono K, Itoh N, Uchio E, Nakamura S, Ohno S. Staining of the internal limiting membrane in macular hole surgery. Arch Ophthalmol. 2000;118:1116-1118.
35. Brooks HL. Macular hole surgery with and without internal limiting membrane peeling. Ophthalmology. 2000;107:1939-1948.
36. Goldbaum MH, McCuen BW, Hanneken AM, Burgess SK, Chen HH. Silicone oil tamponade to seal macular holes without position restrictions. Ophthalmology. 1998;105:2140-2147.
37. Pertile G, Claes C. Silicone oil versus gas for the treatment of full-thickness macular hole. Bull Soc Belge Ophtalmol. 1999;274:31-36.
38. Jumper JM, Gallemore RP, McCuen BW, Toth CA. Features of macular hole closure in the early postoperative period using optical coherence tomography. Retina. 2000;20:232-237.
39. Aaberg TM, Blair CJ, Gass JDM. Macular holes. Am J Ophthalmol. 1970;69:555-562.
40. Aaberg TM. Macular holes: a review. Surv Ophthalmol. 1970;15:139-162.
41. Gass JDM. Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment. Vol 1. 1st ed. St Louis, Mo: Mosby-Year Book Inc; 195-199.
42. Margherio RR, Schepens CL, Macular breaks, I: diagnosis, etiology, and observations. Am J Ophthalmol. 1972;74:219-232.
43. Gass JDM. Idiopathic senile macular hole: its early stages and development. Arch Ophthalmol. 1988;106:629-639.
44. Johnson RN, Gass JDM. Idiopathic macular holes: observations, stages of formation and implications for surgical intervention. Ophthalmology. 1988;95:917-924.
45. Guyer DR, de Bustros S, Diener-West M, Fine SL. The natural history of idiopathic macular holes and cysts. Arch Ophthalmol. 1992;110:1264-1268.
46. Hikichi T, Yoshida A, Akiba J, Konno S, Trempe CL. Prognosis of stage 2 macular holes. Am J Ophthalmol. 1995;119:571-575.
47. Kakehashi A, Schepens CL, Akiba J, Hikichi T, Trempe CL. Spontaneous resolution of foveal detachments and macular breaks. Am J Ophthalmol. 1995;120:767-775.
48. Thompson JT, Glaser BM, Sjaarda RN, Murphy RP. Progression of nuclear sclerosis and long-term visual results after vitrectomy with transforming growth factor beta-2 for macular holes. Am J Ophthalmol. 1995;119:48-54.
49. Ezra E, Arden GB, Riordan-Eva P, Aylward WG, Gregor ZJ. Peripheral field loss following pars plana vitrectomy for stage 2 and 3 macular holes. Br J Ophthalmol. 1996;80:519-525.
50. Boldt HC, Munden PM, Folk JC, Mehaffey MG. Visual field defects after macular hole surgery. Am J Ophthalmol. 1996;122:371-381.
51. Kerrison JB, Haller JA, Elman M, Miller NR. Visual field loss following vitreous surgery. Arch Ophthalmol. 1996;114:564-569.
52. Pendergast SD, McCuen BW. Visual field loss after macular hole surgery. Ophthalmology. 1996;103:1069-1077.
53. Bopp S, Lucke K, Hille U. Peripheral visual field loss after vitreous surgery for macular hole. Graefes Arch Clin Exp Ophthalmol. 1997;235:362-371.
54. Paques M, Massin P, Santiago PY, et al. Visual field loss after vitrectomy for full-thickness macular holes. Am J Ophthalmol. 1997;124:88-94.
55. Ohji M, Nao-I N, Saito Y, Hayashi A, Tano Y. Prevention of visual field defect after macular hole surgery by passing air used for fluid-air exchange through water. Am J Ophthalmol. 1999;127:62-66.
56. Groenewald CP, Wong D, Pearce I, Hiscott P, Grierson I. Nasal epipapillary membrane causing visual field loss following macular hole surgery. Eye. 1998;12:328-330.
57. Cullinane AB, Cleary PE. Prevention of visual field defects after macular hole surgery. Br J Ophthalmol. 2000;84:372-377.
58. Oh KT, Boldt HC, Maturi RK, Folk, JC, Kardon RH. Evaluation of patients with visual field defects following macular hole surgery using multifocal electroretinography. Retina. 2000;20:238-243.
59. Park SS, Marcus DM, Duker JS, et al. Posterior segment complications after vitrectomy for macular hole. Ophthalmology. 1995;102:775-781.
60. Banker AS, Freeman WR, Kim JW, et al. Vision threatening complications of surgery for full-thickness macular holes: Vitrectomy for Macular Hole Study Group. Ophthalmology. 1997;104:1442-1452.
61. Tabandeh H, Chaudhry NA, Smiddy WE. Retinal detachments associated with macular hole surgery: characteristics, mechanisms and outcomes. Retina. 1999;19:281-286.
62. Charles S. Retinal pigment epithelial abnormalities after macular hole surgery [letter]. Retina. 1993;13:176.
63. Poliner LS, Tornambe PE. Retinal pigment epitheliopathy after macular hole surgery. Ophthalmology. 1992;99:1671-1677.
64. Chen C. Glaucoma after macular hole surgery. Ophthalmology. 1998;105:94-99.
65. Banker AS, Freeman WR, Azen SP, Lai MY. A multicentred clinical study of serum as adjunctive therapy for surgical treatment of macular holes: Vitrectomy for Macular Hole Study Group. Arch Ophthalmol. 1999;117:1499-1502.
66. Fine SL. Macular hole: a continuing saga. Arch Ophthalmol. 1999;117:248-249.
67. Standards of Reporting Trials Group. A proposal for structured reporting of randomised controlled trials [published correction appears in JAMA. 1995;273:776]. JAMA. 1994;272:1926-1931.
68. Standards of Reporting Trials Group. A proposal for structured reporting of randomised controlled trials [published correction appears in JAMA. 1995;273:776]. JAMA. 1994;272:1926-1931.
69. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA. 1996;276:637-639.
70. Rennie D. How to report randomised controlled trials: the CONSORT statement [editorial]. JAMA. 1996;276:649.
71. Ferris FL III, Sperduto R. Standardized illumination for visual acuity testing in clinical research. Am J Ophthalmol. 1982;94:97-99.
72. Ferris FL, Kassoff A, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94:91-96.
73. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-1806.
74. Duker JS, Wendel RT, Patel AC, Puliafito CA. Late reopening of macular holes following initially successful vitreous surgery. Ophthalmology. 1994;101:1373-1378.
75. Del Priore LV, Kaplan HJ, Bonham FD. Laser photocoagulation and fluid-gas exchange for recurrent macular hole. Retina. 1994;14:381-382.
76. Paques M, Massin P, Santiago PY, et al. Late reopening of successfully treated macular holes. Br J Ophthalmol. 1997;81:658-662.
77. Christmas NJ, Smiddy WE, Flynn HW. Reopening of macular holes after initially successful repair. Ophthalmology. 1998;105:1835-1838.
78. Paques M, Massin P, Blain P, Duquesnoy AS, Gaudric A. Long-term incidence of reopening of macular holes. Ophthalmology, 2000;107:760-765.
79. James M, Fenman SS. Macular holes. Graefes Arch Clin Exp Ophthalmol. 1980;215:59-63.
80. McDonnell PJ, Fine SL, Hillis AI. Clinical features of idiopathic macular cysts and holes. Am J Ophthalmol. 1982;93:777-786.
81. Morgan CM, Schatz H. Idiopathic macular holes. Am J Ophthalmol. 1985;99:437-444.
82. Scott RA, Ezra E, West JF, Gregor ZJ. Visual and anatomical results of surgery for long standing macular holes. Br J Ophthalmol. 2000;84:150-153.